Figure S1

Patients’ disposition

Enrolled n=118

IFNβ-1a i.m. n=42
- Early dropouts 5
  - Adverse event 2
  - Disease worsening 1
  - Investigator decision 1
  - Withdrew consent 1

IFNβ-1a 44 μg s.c. n=40
- Early dropouts 6
  - Adverse event 2
  - Disease worsening 2
  - Non-compliance 1
  - Withdrew consent 1

IFNβ-1b s.c. n=36
- Early dropouts 7
  - Adverse event 3
  - Disease worsening 1
  - Withdrew consent 3

Early dropouts before T12 = 18 early dropouts

Dropouts 7
- Adverse event 2
- Disease worsening 2
- Lost to follow-up 1
- Withdrew consent 2

Dropouts 6
- Disease worsening 4
- Investigator decision 1
- Lost to follow-up 1

Dropouts 4
- Adverse event 2
- Disease worsening 2

Early dropouts before T24 = 18 + 17 = 35 dropouts

Dropouts 11
- Investigator decision 6
- Lost to follow-up 1
- Withdrew consent 4

Dropouts 8
- Disease worsening 1
- Investigator decision 2
- Lost to follow-up 3
- Non-compliance 1
- Withdrew consent 1

Completed study n=19

Completed study n=20

Completed study n=18

Dropouts before T36 (after study extension) = 18 + 17 + 26 = 61 dropouts

Total = 57